Why the study?
Refractory ventricular fibrillation after acute myocardial infarction has a low survival rate and lacks established effective treatment strategies beyond traditional ACLS.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
May inform rescue strategies for refractory VF in STEMI; hypothesis-generating and requires prospective validation before clinical adoption.
Ventricular fibrillation (VF) is a life-threatening cardiac arrhythmia that can lead to loss of cardiac function and sudden cardiac death. The most common cause of VF is ischemic cardiomyopathy, especially in the context of an acute coronary event. Prompt treatment with resuscitation and defibrillation can be lifesaving. Refractory VF, or pulseless ventricular tachycardia (pVT), refers to cases that do not respond to traditional advanced cardiac life-support (ACLS) measures, and it has a low survival rate. Some new life-saving interventions and novel techniques have been proposed as viable treatment options for patients presenting with refractory VF/pVT out-of-hospital cardiac arrest; these include extracorporeal membrane oxygenation (ECMO), esmolol, stellate ganglion block (SGB), and double sequential defibrillation (DSD). Recently, DSD has been discussed and used more frequently, but its survival rate is still not promising. We report a case of refractory VF caused by acute myocardial infarction that was treated with ACLS, DSD, ECMO, and cardiac catheterization in sequence, with a successful outcome.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2022) conducted a case report in Refractory Ventricular Arrhythmia in STEMI (n=1). Combination of multidisciplinary therapies (ACLS, DSD, ECMO, and PCI) was evaluated on Return of spontaneous circulation (ROSC) and survival.
Synapse has enriched 10 related papers. Consider them for comparative context: